Valeant Pharmaceuticals International Inc. is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, according to people familiar with the matter, as the Canadian drugmaker scrambles to raise cash and reduce debt.
The company is considering the disposal of Obagi Medical Products Inc., a dermatology company it acquired in 2013, as well as Provenge, a treatment for advanced prostate cancer that was purchased last year, said the people, who asked not to be identified because the matter is private.
Valeant may also sell drugs acquired from Marathon Pharmaceuticals last year, one of the people said.
The company is considering the disposal of Obagi Medical Products Inc., a dermatology company it acquired in 2013, as well as Provenge, a treatment for advanced prostate cancer that was purchased last year, said the people, who asked not to be identified because the matter is private.
Valeant may also sell drugs acquired from Marathon Pharmaceuticals last year, one of the people said.
